In silico description of differential enantioselectivity in methoxychlor O-demethylation by CYP2C enzymes

被引:10
作者
Bikadi, Zsolt [1 ]
Hazai, Eszter [1 ]
机构
[1] Virtua Drug Ltd, H-1015 Budapest, Hungary
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2008年 / 1780卷 / 09期
关键词
heme protein; CYP2C; stereoselective metabolism; molecular dynamic; molecular docking; homology model;
D O I
10.1016/j.bbagen.2008.06.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Methoxychlor undergoes metabolism by cytochrome P450 (CYP) enzymes forming a chiral mono-phenolic derivative (Mono-OH-M) as main metabolite. In the current study, members of the CYP2C family were examined for their chiral preference in Mono-OH-M formation. CYP2C9 and CYP2C19 possessed high enantioselectivity favoring the formation of S-Mono-OH-M; CYP2C3 showed no enantioselectivity, whereas CYP2C5 slightly favored the formation of R-Mono-OH-M. Molecular modeling calculations were utilized in order to explain the observed differences in chiral preference of CYP2C enzymes. Molecular docking calculations could describe neither the existence of chiral preference in metabolism, nor the enantiomer which is preferentially formed. Molecular dynamic calculations were also carried out and were found to be useful for accurate description of chiral preference in biotransformation of methoxychlor by CYP2C enzymes. An in silico model capable of predicting chiral preference in cytochrome P450 enzymes in general can be developed based on the analysis of the stability and rigidity parameters of interacting partners during molecular dynamic simulation. (c) 2008 Elsevier B.V. All Fights reserved.
引用
收藏
页码:1070 / 1079
页数:10
相关论文
共 40 条
[1]   Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes [J].
Backes, WL ;
Kelley, RW .
PHARMACOLOGY & THERAPEUTICS, 2003, 98 (02) :221-233
[2]   Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily [J].
Barbosa-Sicard, E ;
Markovic, M ;
Honeck, H ;
Christ, B ;
Muller, DN ;
Schunck, WH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (04) :1275-1281
[3]  
Bikadi Zsolt, 2007, Curr Drug Discov Technol, V4, P282, DOI 10.2174/157016307783220549
[4]  
BULGER WH, 1985, MOL PHARMACOL, V27, P115
[5]   Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases [J].
Cashman, JR .
DRUG METABOLISM REVIEWS, 1998, 30 (04) :675-707
[6]   Cytochrome P450 in silico: An integrative modeling approach [J].
de Graaf, C ;
Vermeulen, NPE ;
Feenstra, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :2725-2755
[7]   Phe120 contributes to the regiospecificity of cytochrome P450 2D6:: mutation leads to the formation of a novel dextromethorphan metabolite [J].
Flanagan, JU ;
Maréchal, JD ;
Ward, R ;
Kemp, CA ;
Mclaughlin, LA ;
Sutcliffe, MJ ;
Roberts, GCK ;
Paine, MJI ;
Wolf, CR .
BIOCHEMICAL JOURNAL, 2004, 380 :353-360
[8]   Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: Possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes [J].
Hazai, E ;
Kupfer, D .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) :157-164
[9]   Improved binding of cytochrome P450cam substrate analogues designed to fill extra space in the substrate binding pocket [J].
Helms, V ;
Deprez, E ;
Gill, E ;
Barret, C ;
Hoa, GHB ;
Wade, RC .
BIOCHEMISTRY, 1996, 35 (05) :1485-1499
[10]   Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: Pathways involving a novel catechol metabolite [J].
Hu, YD ;
Kupfer, D .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (09) :1035-1042